Epilepsy gene variants: do they influence treatment decisions?

New data have shown how identifying the presence of variants in epilepsy-related genes can significantly influence treatment choices in pediatric patients with epilepsy.

Researchers at the Children’s Medical Center in Dallas, Texas, USA, reviewed the results of next-generation sequencing (NGS), including SCN1A and SCN8A, in pediatric patients with epilepsy. Variants in SCN1A and SCN8A were classified as variants of unknown significance (VUS), likely pathogenic (LP), or pathogenic (P).

The main findings of the study were as follows:

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.